{"product_id":"inhibitors-in-patients-with-haemophilia-isbn-9780632064779","title":"Inhibitors in Patients with Haemophilia","description":"Edited by an orthopaedic surgeon and a haematologist who are leading specialists in the treatment of haemophilia, Inhibitors in Patients with Haemophilia reviews the different haemostatic products and protocols for the control of bleeding and surgery in haemophilic patients with inhibitors.\u003cbr\u003e \u003cp\u003eThe book draws together in a single volume all of the clinical issues involved in the treatment of inhibitors from numerous specialists worldwide. It will be an invaluable resource for all those treating inhibitors in people with haemophilia.\u003c\/p\u003e  Contributors. \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003eHAEMATOLOGY.\u003c\/p\u003e \u003cp\u003e1 Natural history of inhibitor in severe haemophilia A and B: incidence and prevalence.\u003c\/p\u003e \u003cp\u003eJeanne Lusher (USA).\u003c\/p\u003e \u003cp\u003e2 Characterisation of inhibitors in congenital haemophilia.\u003c\/p\u003e \u003cp\u003eKathelijne Peerlinck and Marc Jacquemin (Belgium).\u003c\/p\u003e \u003cp\u003e3 Incidence and prevalence of inhibitors and type of blood product in haemophilia A.\u003c\/p\u003e \u003cp\u003eChristine Lee and Thynn Thynn Yee (UK).\u003c\/p\u003e \u003cp\u003e4 Genetic basis of inhibitor development in severe haemophilia A and B.\u003c\/p\u003e \u003cp\u003eEdward Tuddenham (UK) and Johannes Oldenburg (Germany).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003eMANAGEMENT OF TREATMENT.\u003c\/p\u003e \u003cp\u003e5 Therapeutic products: human FVIII, porcine FVIII, prothrombin complex concentrates, activated prothrombin complex concentrates and recombinant FVIIa.\u003c\/p\u003e \u003cp\u003eThierry Lambert (France).\u003c\/p\u003e \u003cp\u003e6 Methods: plasmapheresis and protein A immuno-adsorption.\u003c\/p\u003e \u003cp\u003eEric Berntorp (Sweden).\u003c\/p\u003e \u003cp\u003e7 Venous access in children with inhibitors.\u003c\/p\u003e \u003cp\u003eRolf Ljund (Sweden).\u003c\/p\u003e \u003cp\u003eIMMUNETOLERANCE.\u003c\/p\u003e \u003cp\u003e8 Immunetolerance: high dose regimen.\u003c\/p\u003e \u003cp\u003eHans Brackmann and Thomas Wallny (Germany) (To be agreed).\u003c\/p\u003e \u003cp\u003e9 Immunetolerance: low dose regimen.\u003c\/p\u003e \u003cp\u003eEveline Mauser-Bunschotten (Netherlands).\u003c\/p\u003e \u003cp\u003e10 Immunotolerance and choice of concentrates.\u003c\/p\u003e \u003cp\u003eWolfgang Kreutz (Germany).\u003c\/p\u003e \u003cp\u003e11 Immunetolerance regimen: the North America registry (To be agreed).\u003c\/p\u003e \u003cp\u003eDonna DiMichele (USA).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003eMEDICAL MANAGEMENT OF BLEEDING EPISODES.\u003c\/p\u003e \u003cp\u003e12 Treatment of bleeding episodes in children.\u003c\/p\u003e \u003cp\u003eJoan Tusell (Spain).\u003c\/p\u003e \u003cp\u003e13 General medical management of bleeding episodes: haemarthroses, muscle haematoma, mucocutaneous bleed, haematuria.\u003c\/p\u003e \u003cp\u003eManuel Quintana (Spain).\u003c\/p\u003e \u003cp\u003e14 Life- and limb-threatening bleeding episodes and intracranial bleeds.\u003c\/p\u003e \u003cp\u003eSam Schulman (Sweden).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003eINHIBITORS IN HAEMOPHILIA B.\u003c\/p\u003e \u003cp\u003e15 Inhibitors in haemophilia B patients.\u003c\/p\u003e \u003cp\u003eIndia Warrier (USA).\u003c\/p\u003e \u003cp\u003e16 Inhibitors in mild\/moderate haemophilia.\u003c\/p\u003e \u003cp\u003eCharles Hay (UK).\u003c\/p\u003e \u003cp\u003e17 Acquired inhibitors to FVIII.\u003c\/p\u003e \u003cp\u003eCraig Kessler (USA).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003eMUSCULOSKELETAL ISSUES.\u003c\/p\u003e \u003cp\u003e18 Pathogenesis of musculoskeletal complications of haemophilia.\u003c\/p\u003e \u003cp\u003eE C Rodriguez-Merchan (Spain).\u003c\/p\u003e \u003cp\u003e19 Orthopaedic management of haemarthroses.\u003c\/p\u003e \u003cp\u003eE C Rodriguez-Merchan (Spain).\u003c\/p\u003e \u003cp\u003e20 Synoviorthesis with Rifampicin.\u003c\/p\u003e \u003cp\u003eHoracio Caviglia (Argentina) and F Fernandez-Palazzi (Venezuela).\u003c\/p\u003e \u003cp\u003e21 Radiosynoviorthesis.\u003c\/p\u003e \u003cp\u003eEric Berntorp (Sweden).\u003c\/p\u003e \u003cp\u003e22 Musculoskeletal MRI.\u003c\/p\u003e \u003cp\u003eRachel Nuss and Jerome Wiedel (USA).\u003c\/p\u003e \u003cp\u003e23 Iliopsoas haematomas and limb compartment syndromes.\u003c\/p\u003e \u003cp\u003eMichael Heim (Israel).\u003c\/p\u003e \u003cp\u003e24 Pseudotumours.\u003c\/p\u003e \u003cp\u003eMarvin Gilbert (USA).\u003c\/p\u003e \u003cp\u003e25 Haemophilia patients with inhibitors: a rheumatologist´s point of view.\u003c\/p\u003e \u003cp\u003eJohn York (Australia).\u003c\/p\u003e \u003cp\u003e26 Rehabilitation.\u003c\/p\u003e \u003cp\u003eFelipe Querol and José Aznar (Spain).\u003c\/p\u003e \u003cp\u003e27 Physiotherapy.\u003c\/p\u003e \u003cp\u003eKaren Beeton (UK).\u003c\/p\u003e \u003cp\u003e28 Elective orthopaedic surgery in patients with high responding inhibitors-.\u003c\/p\u003e \u003cp\u003eIvan Hvid, J Soballe and J Ingerslev (Denmark).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003eGENERAL SURGERY.\u003c\/p\u003e \u003cp\u003e29 General and emergency surgery in patients with high responding inhibitors.\u003c\/p\u003e \u003cp\u003eOwen Smith \u0026amp; Barry White (Ireland).\u003c\/p\u003e \u003cp\u003e30 Dental extractions.\u003c\/p\u003e \u003cp\u003eUri Martinowitz (Israel).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003ePSYCHOSOCIAL ISSUES.\u003c\/p\u003e \u003cp\u003e31 Psychological issues.\u003c\/p\u003e \u003cp\u003ePilar Arranz (Spain).\u003c\/p\u003e \u003cp\u003e.\u003c\/p\u003e \u003cp\u003e32 GENERAL STRATEGY FOR MANAGEMENT OF INHIBITOR PATIENTS.\u003c\/p\u003e \u003cp\u003eInga Scharrer (Germany).\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eE. C. Rodriquez-Merchan\u003c\/strong\u003e is the editor of \u003cem\u003eInhibitors in Patients with Haemophilia\u003c\/em\u003e, published by Wiley. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eChristine A. Lee\u003c\/strong\u003e is the editor of \u003cem\u003eInhibitors in Patients with Haemophilia\u003c\/em\u003e, published by Wiley.   Edited by an orthopaedic surgeon and a haematologist who are leading specialists in the treatment of haemophilia, Inhibitors in Patients with Haemophilia reviews the different haemostatic products and protocols for the control of bleeding and surgery in haemophilic patients with inhibitors.\u003cbr\u003e \u003c\/p\u003e\u003cp\u003eThe book draws together in a single volume all of the clinical issues involved in the treatment of inhibitors from numerous specialists worldwide. It will be an invaluable resource for all those treating inhibitors in people with haemophilia.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989424586981,"sku":"NP9780632064779","price":338.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780632064779.jpg?v=1761784053","url":"https:\/\/k12savings.com\/products\/inhibitors-in-patients-with-haemophilia-isbn-9780632064779","provider":"K12savings","version":"1.0","type":"link"}